Our strategy to inhibit the MCP-1/CCR2 axis, in addition to the potentially unique combination with CCR4 receptor K/O, remarkably delayed MBM progression, activated the BME toward anticancer and proinflammatory phenotypes, and promoted infiltration of CD8+ T cells, altering the melanoma-brain cell landscape. This evidence concerns the gene CCL2 and melanoma.